For Q1 FY2026 ended March 31, 2026, Autolus Therapeutics plc reported revenue of $26.2 million, a 191.9% increase year-over-year. Net loss was $71.6 million, slightly wider than the prior year. Operating loss improved to $59.5 million, and diluted EPS was -$0.27. Cash and cash equivalents stood at $130.9 million, with equity of $108.8 million.
•Revenue surged 191.9% YoY to $26.2 million.
•Net loss widened 2.0% to $71.6 million.
•Operating loss improved 8.8% to $59.5 million.
•Cash and equivalents totaled $130.9 million as of March 31, 2026.
Informational summary based on SEC XBRL figures · generated by deepseek-v4-flash. Not investment advice.
Autolus Therapeutics plc, a clinical-stage biopharmaceutical company develops T cell therapies for the treatment of cancer and autoimmune diseases in the United Kingdom and globally.
The company offers AUCATZYL, a gene therapy product consisting of autologous T cells that are transduced with a lentiviral vector to express a novel anti-CD19 chimeric antigen receptor. It also develops obe-cel, which is in phase 1 to treat systemic lupus erythematosus, progressive multiple sclerosis, B-NHL and CLL, and CNS lymphoma.
Its portfolio also includes obe-cel, which is in phase 2 to treat pediatric B-ALL and lupus nephritis, AUTO1/22 to treat pediatric B-ALL, which is phase 1, AUTO8, which is in phase 1 to treat multiple myeloma and light chain amyloidosis, AUTO4/5, which is in preclinical stage to treat peripheral TCL, AUTO6NG, which is in phase 1 to treat neuroblastoma, and AUTO9, which is in preclinical stage to treat acute myeloid leukemia. Incorporated in 2014, the company is headquartered in London, the United Kingdom.
Autolus Therapeutics plc is a clinical-stage biopharmaceutical company focused on developing T cell therapies for the treatment of cancer and autoimmune diseases. The company's lead product, AUCATZYL, is a gene therapy consisting of autologous T cells transduced with a lentiviral vector to express a novel anti-CD19 chimeric antigen receptor (CAR). Autolus also has a robust pipeline including obe-cel, which is in phase 1 trials for systemic lupus erythematosus, progressive multiple sclerosis, B-NHL, CLL, and CNS lymphoma, and in phase 2 for pediatric B-ALL and lupus nephritis. Other candidates include AUTO1/22 (phase 1 for pediatric B-ALL), AUTO8 (phase 1 for multiple myeloma and light chain amyloidosis), AUTO4/5 (preclinical for peripheral TCL), AUTO6NG (phase 1 for neuroblastoma), and AUTO9 (preclinical for acute myeloid leukemia).
On which stock exchange is Autolus Therapeutics (AUTL) listed and in what currency?
Autolus Therapeutics plc is listed on the Nasdaq Global Select Market (NasdaqGS) under the ticker symbol AUTL. The company's shares trade in US Dollars (USD), reflecting its primary listing in the United States. As a clinical-stage biopharmaceutical company headquartered in the United Kingdom, Autolus chose to list on Nasdaq to access a deep pool of investors familiar with the biotechnology sector. The use of USD facilitates trading for international investors and aligns with the company's operations, as it conducts business globally and reports its financial results in US dollars.
What sector and industry does Autolus Therapeutics (AUTL) operate in?
Autolus Therapeutics plc operates in the Healthcare sector, specifically within the Biotechnology industry. As a clinical-stage biopharmaceutical company, Autolus focuses on developing innovative T cell therapies for cancer and autoimmune diseases. The biotechnology industry is characterized by high research and development costs, long development timelines, and significant regulatory oversight. Autolus's work in cell therapy, particularly CAR-T technology, places it at the forefront of precision medicine, aiming to harness the patient's own immune system to fight diseases. The company's pipeline targets both hematologic malignancies and solid tumors, as well as autoimmune conditions, reflecting a broad therapeutic focus within the biotech space.
Where is Autolus Therapeutics (AUTL) headquartered and what markets does it serve?
Autolus Therapeutics plc is headquartered in London, United Kingdom, and serves markets globally, with a primary focus on the United Kingdom and other international regions. The company was incorporated in 2014 and operates as a clinical-stage biopharmaceutical entity, meaning its therapies are still in development and not yet commercially available. Autolus's research and clinical trials are conducted across multiple countries, including the UK, the US, and other regions, as it seeks to bring its T cell therapies to patients worldwide. The company's geographic presence is supported by its listing on the Nasdaq exchange, which provides access to US capital markets and investors.
What is the business model of Autolus Therapeutics (AUTL) and how does it generate revenue?
Autolus Therapeutics plc is a clinical-stage biopharmaceutical company, meaning it currently does not generate revenue from product sales, as its therapies are still in development and have not received regulatory approval for commercialization. The company's business model focuses on research and development of T cell therapies for cancer and autoimmune diseases. Autolus generates revenue primarily through collaboration agreements, licensing deals, and research grants. For example, the company may partner with other pharmaceutical firms to co-develop or license its candidates. Additionally, Autolus may receive milestone payments or royalties from such partnerships. Until its products reach the market, the company relies on equity financing, debt, and strategic collaborations to fund its operations and clinical trials.